---

On February 6, 2026, the U.S. Food and Drug Administration (FDA) announced plans to take action against companies selling non-FDA-approved GLP-1 drugs, including some compounded versions being widely marketed online.

The FDA said these products are being promoted as alternatives to approved drugs like Ozempic and Wegovy, but the agency cannot confirm their safety, quality, or effectiveness. Some of these drugs are made using GLP-1 ingredients that have not been approved by the FDA, which raises serious consumer safety concerns.

The agency also warned companies—such as certain telehealth brands and compounding pharmacies—that they cannot advertise these products as “generic,” “the same as,” or clinically proven. According to the FDA, these claims are misleading and violate federal law.

The FDA says it will use its full legal authority to stop illegal marketing and sales. Companies that continue to make unproven claims or sell unapproved compounded GLP-1 drugs could face seizures, court orders, or other legal action—without additional warning.

The FDA emphasized that these steps are meant to protect patients from unsafe or misleadingly marketed weight-loss and diabetes drugs and to ensure that only properly reviewed medications are sold to the public.